Delirium, Dementia, Amnestic, Cognitive Disorders  >>  cerlapirdine (PF-5212365)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cerlapirdine (PF-5212365) / Pfizer
NCT00481520: Study Evaluating the Safety,Tolerability, PK and PD of SAM-531 in the Subjects With Mild to Moderate Alzheimer's Disease

Completed
2
72
US
SAM-531, placebo
Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer Disease
01/08
01/08
NCT00895895: Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease

Terminated
2
526
Japan, US, Europe, RoW
Placebo, SAM-531 1.5 mg, SAM-531 3.0 mg, SAM-531 5.0 mg, Donepezil
Pfizer
Alzheimer Disease
05/11
05/11

Download Options